Markets
CBM

Corbus Concludes Phase II study of Cystic Fibrosis Candidate

A generic image of stock metrics
Credit: Shutterstock photo

Corbus Pharmaceuticals Holdings, Inc.CRBP , recently announced that it has concluded Phase II trial evaluating pipeline candidate, JBT-101 (resunab), for the treatment of cystic fibrosis (CF).

Corbus' share price has gained 17.8% in the past one month, outperforming the Zacks classified Medical-Drugs industry which has witnessed a gain of 2.5% gain in the same time frame.

The Phase II trial is a multi-center, double-blinded, randomized, placebo-controlled study. The main aim of the trial was to test safety and tolerability of JBT-101 in adults with CF who had forced expiratory volume in 1 second (FEV1) percent predicted at least 40%, without regard to their CFTR mutation, infecting pathogen, or baseline treatment. The company expects to report top-line data from the study in first-quarter 2017.

Resunab, is Corbus' lead product candidate. It is a first-in-class, synthetic oral endocannabinoid-mimetic drug that targets chronic inflammation and fibrotic processes by triggering an endogenous pathway called "Resolution of Inflammation."

Notably, resunab has been granted Fast Track status and Orphan Drug Designation for the treatment of CF, by the FDA and the EU, respectively. Additionally, resunab is currently being evaluated in a Phase II, 12-month open label extension study in systemic sclerosis, a Phase II study in skin-predominant dermatomyositis, while another Phase II study in systemic lupus erythematosus (SLE) is expected to start in first-quarter 2017.

Last month, the company reported positive top-line data results from its Phase II study in diffuse cutaneous systemic sclerosis ("systemic sclerosis"), displaying clear signal of clinical benefit with JBT-101. The candidate outperformed placebo in the American College of Rheumatology (ACR) Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) score, reaching 33% at week 16, versus 0% for placebo.

Key Picks

Investors looking for some well-positioned stocks in the health care sector could consider Cambrex Corporation CBM , Heska Corporation HSKA and Anika Therapeutics Inc. ANIK . While Cambrex and Heska sport a Zacks Rank #1 (Strong Buy), Anika carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.

Heska's earnings estimates improved 19.5% for 2016 and 10.9% for 2017 in the last 60 days. The company posted a positive earnings surprise in each of the four trailing quarters, with an average beat of 301.64%. Its share price has increased 88.3% year to date.

Cambrex's earnings estimates increased 3.7% for 2016 and 5.2% for 2017 in the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters, with an average beat of 19.78%. Its share price is up 13.7% year to date.

Anika's earnings estimates for 2016 and 2017 were up 3.9% and 0.5%, respectively in the last 60 days. The company has recorded a positive earnings surprise in each of the last four quarters, the average being 33.14%. Its share price is up 28.9% year to date.

CORBUS PHARMACT Price

CORBUS PHARMACT Price | CORBUS PHARMACT Quote

Zacks' Best Private Investment Ideas

In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?

Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ANIKA THERAPEUT (ANIK): Free Stock Analysis Report

CAMBREX CORP (CBM): Free Stock Analysis Report

HESKA CORP (HSKA): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

CBM ANIK CRBP HSKA

Other Topics

Stocks